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Abstract: Introduction: Screening for synthetic lethality markers has demonstrated that the inhibition
of the cell cycle checkpoint kinases WEE1 together with CHK1 drastically affects stability of the
cell cycle and induces cell death in rapidly proliferating cells. Exploiting this finding for a possible
therapeutic approach has showed efficacy in various solid and hematologic tumors, though not
specifically tested in acute lymphoblastic leukemia. Methods: The efficacy of the combination
between WEE1 and CHK1 inhibitors in B and T cell precursor acute lymphoblastic leukemia (B/T-ALL)
was evaluated in vitro and ex vivo studies. The efficacy of the therapeutic strategy was tested in
terms of cytotoxicity, induction of apoptosis, and changes in cell cycle profile and protein expression
using B/T-ALL cell lines. In addition, the efficacy of the drug combination was studied in primary
B-ALL blasts using clonogenic assays. Results: This study reports, for the first time, the efficacy
of the concomitant inhibition of CHK1/CHK2 and WEE1 in ALL cell lines and primary leukemic
B-ALL cells using two selective inhibitors: PF-0047736 (CHK1/CHK2 inhibitor) and AZD-1775 (WEE1
inhibitor). We showed strong synergism in the reduction of cell viability, proliferation and induction
of apoptosis. The efficacy of the combination was related to the induction of early S-phase arrest
and to the induction of DNA damage, ultimately triggering cell death. We reported evidence that
the efficacy of the combination treatment is independent from the activation of the p53-p21 pathway.
Moreover, gene expression analysis on B-ALL primary samples showed that Chek1 and Wee1 are
significantly co-expressed in samples at diagnosis (Pearson r = 0.5770, p = 0.0001) and relapse (Pearson
r = 0.8919; p = 0.0001). Finally, the efficacy of the combination was confirmed by the reduction in
clonogenic survival of primary leukemic B-ALL cells. Conclusion: Our findings suggest that the
combination of CHK1 and WEE1 inhibitors may be a promising therapeutic strategy to be tested in
clinical trials for adult ALL.
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1. Introduction
Currently, the standard therapeutic regimens for adult acute lymphoblastic leukemia (ALL) patients
still involve DNA-damaging agents such as conventional chemotherapy agents (Hyper-CVAD) [1] with
or without the use of specific kinase inhibitors for particular ALL sub-types. Although the initial overall
response rate is high (90%) in adult ALL patients, a large percentage of them frequently relapse. Thus,
there is a strong need to improve the efficacy of treatments or to identify novel therapeutic strategies that
lead to increased durability. For several years different research groups have focused on the biological
pathways underlying cancer cell response to DNA damaging therapeutics [2,3]. They discovered that all
eukaryotic cells respond to DNA damage by activating DNA damage response (DDR) pathways which
consist of cell cycle checkpoints, DNA repair and apoptosis mediators. The overall function of DDR
pathways is to prevent cells from initiating cell division with damaged DNA, which would otherwise
compromise the DNA of the daughter cells. If DDR pathways play a tumor suppressor role in normal
cells, their excessive activation in cancer cells has been associated with increased genetic instability
and chemo-resistance, due to the upregulation of DNA-repair mechanisms. Therefore, components
of the DDR pathway are interesting targets of cancer cells. The inhibition of cell cycle checkpoint
regulators, such as CHK1, CHK2 and WEE1 kinases, has become a promising strategy to kill cancer
cells mostly by enhancing the toxicity of DNA-damaging agents [4–7]. Several studies showed that all
three kinases are involved in the regulation of both intra-S and G2/M checkpoints [8–13]. Biologically,
these three kinases cooperate at different levels to regulate the activity of common substrates such as
the CDK2-CYCLIN E (S phase) and CDK1-CYCLIN A/B (G2/M phase) complexes [14]. It has been
reported that the inhibition of CHK1, CHK2 or WEE1, as monotherapy or in combination with DNA
damaging agents, reduces cell viability and induces apoptosis in preclinical models of ALL [15–20].
Recently, an interspecies study highlighted the synthetic lethal interaction between CHK1/CHK2
and WEE1 [21]. The mechanism of action is based on the drug-to-drug synthetic lethality, in which
the concomitant inhibition of two independent pathways results in a synergic inhibition of the cell
viability. Recent studies on different tumors, including onco-hematological models, showed that the
simultaneous inhibition of CHK1 and WEE1 causes synergic inhibition of tumor growth and induction
of apoptosis [20,22–25]. However, none of them focused on ALL. Since WEE1 and CHK1 are important
for ALL cell viability and their inhibition results in the collapse of replication forks and impairs cell
cycle progression [26,27], we set out to explore this potential therapeutic strategy on ALL cell lines and
primary leukemic cells, highlighting the mechanistic cooperativity of the two inhibitors.
2. Methods
2.1. Drugs and Cell Lines
AZD-1775, PF-00477736 and methotrexate were purchased from MedChemExpress (Monmouth
Junction, NJ, USA). Clofarabine was obtained from Sigma-Aldrich (Darmstadt, Germany). Both
NALM-6 and RPMI-8402 were cultured in complete RPMI-1640 (Invitrogen, Waltham, MA, USA)
medium containing 1% l-glutamine (Sigma-Aldrich), penicillin (100 U/mL, Gibco, Waltham, MA, USA)
and streptomycin (100 µg/mL, Gibco) and 10% fetal bovine serum (Gibco).
2.2. Viability and Combination Index Analysis
The cell viability analysis of AZD-1775 and PF-00477736 in monotherapy was performed as
previously reported [28,29]. For combination index assays, cells were treated simultaneously with
increasing concentration of AZD-1775 and PF-00477736 for 24, 48 and 72 h and the reduction of the
cell viability was performed using CellTiter 96® AQueous One Solution Cell Proliferation Assay
(MTS, Promega, Madison, WI, USA). The additive, synergistic, and antagonistic effect of the drug
combinations was evaluated according to the Chou-Talaley equation [30], using Compusyn Software
(ComboSyn Incorporated, Paramus, NJ, USA). Based on developer instructions we defined: synergism
where CI < 1; additivity where CI = 1; antagonism where CI > 1. To evaluate the effect of the combination
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of the cell proliferation, cells were seeded in 6-well plates at a concentration of 0.2 × 106 cells/mL and
treated with the two compounds in single agent or in combination (DAY 0). Cells were counted every
24 h for 6 days of continuous drug exposure. Proliferation assays were performed in triplicate and
independent experiments were performed at least 3 times.
2.3. Cell Cycle and Apoptosis Analysis
The induction of cell apoptosis was evaluated using Annexin V-FITC and Propidium Iodide (PI)
staining according to the manufacturer’s instructions (Roche, Basel, Switzerland). Cells were seeded
for 24 h at 37 ◦C in 12-well plates at 0.5 × 106 cells/mL with AZD-1775 (both cell lines: 185 nM) and/or
PF-00477736 (NALM-6: 250 nM; RPMI-8402: 25 nM). A minimum of 10,000 cells was evaluated for
every experimental condition. Statistical analyses were obtained using the mean percentage of Annexin
V-PI-positive cells and standard error measurements were calculated from at least three independent
experiments. Cell cycle analyses were performed using the same experimental conditions reported
above for the apoptosis analysis. After 24 h of incubation, cells fixed using 70% ethanol and stored at
−20 ◦C for 24 h for further cytometry analysis. To perform cell cycle analysis, ethanol was removed by
PBS wash and the cells were stained with PI staining mix for 30 min at 37 ◦C. Cell cycle phases were
identified and quantified using Flowing software (Cell Imaging Core, Turku Centre for Biotechnology,
Turku, Finland) and ModfiT software (Verity Software House, Topsham, ME, USA).
2.4. BrdU Incorporation Assay
In order to quantify the proliferation index, NALM-6 and RPMI-8402 cell lines were stained
using BrdU staining (according to datasheet instruction). Cells were seeded at 0.5 × 106 cells/mL
on a 6 wells plate and treated with AZD-1775 (both cell lines: 185 nM) and PF-00477736 (NALM-6:
250 nM; RPMI-8402: 25 nM) for 22 h at 37 ◦C. After 22 h of incubation, cells were incubated with BrdU
labeling solution for further 2 h and then fixed. Samples were analyzed using luminomer (Infinite
200 PRO NanoQuant Microplate Reader, Tecan, Männedorf, Switzerland). Row data (RLU, relative
luminescence unit) were normalized and expressed as a percentage of the control cells.
2.5. Clonogenic Assay and Morphological Analysis
Primary mononuclear cells isolated from the bone marrow (BM) of adult BCR/ABL1-positive/
-negative B-ALL patients (n = 7) at diagnosis or relapse (not paired) were seeded at 0.75 × 105 cells/well
in methylcellulose-based medium (StemMACS HSC-CFU complete with Epo; Miltenyi Biotec, Bergisch
Gladbach, Germany). The study was approved by the local Ethical committee (n. 112/2014/U/Tess).
Informed consent was obtained in accordance with the Declaration of Helsinki. Cells were incubated
with PF-00477736 (0.1 µM) with or without AZD-1775 (0.1 µM) for 14 days at 37 ◦C. Colonies were
counted and the reduction of the clonogenic capacity was calculated as a percentage of the number of
colonies in the control (number of colonies in the treatment/number of colonies in the control × 100).
To better define the effect of the in vitro treatments on BM hematopoietic precursors and on primary
leukemic B-ALL cells, at the end of the clonogenic assays (n = 3), the colonies were harvested, washed
in PBS to remove the methylcellulose, seeded on poly-D-lysine-coated cover-slides and stained with
MC Grunwald & Giemsa solution (J.T.Baker, ThermoFisher Scientific, Waltham, MA, USA). An average
number of 300 cell/experimental condition was evaluated to quantify the number of cells.
2.6. Quantitative PCR of CHK1, CHK2 and WEE1 in Primary B-ALL Samples
Total RNA was extracted using simply RNA Blood Kit (Promega) from primary leukemic
cells isolated from the BM of the seven B-ALL cases used for the above described clonogenic
assays. One µg of total RNA was used as template for reverse transcription according to the
SuperScript IV protocol (ThermoFisher Scientific). The equivalent cDNA was analyzed by Taqman
Gene Expression assays-single tube assays (ref. 4331182- Applied Biosystems, Foster City, CA,
USA) for CHK1, CHK2 and WEE1 expression, using GUS-β (Beta-Glucuronidase) as control gene
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(ENF1102 5′ GAAAATATGTGGTTGGAGAGCTCATT3′, ENR1162 5′CCGAGTGAAGATCCCCTTTT
TA3′, ENPr1142Fam CCAGCACTCTCGTCGGTGACTGTTCA-Joe). All reactions were performed in
triplicate (both genes of interest and CG) on a Taqman 7900HT real-time PCR machine (ThermoFisher
Scientific). The relative gene expression values for each gene of interest were calculated by ∆∆CT
method following the recommendations provided by thermofisher.com/qpcreducation on RQ Manager
application (SDS 2.4 software, Applied Biosystems). Furthermore, the differential expression value
between CHK1, CHK2 and WEE1 genes at disease state (diagnosis or relapse) was determined by fold
change formula 2-∆∆CT.
2.7. Immunoblotting
Immunoblotting analyses were performed on cells previously incubated with cell lysis buffer
(#9803s, Cell Signaling Technology Danvers, MA, USA) for 30 min. Electrophoresis was performed
using Mini-Protean TGX stain-free precast gels, blotted to nitrocellulose membranes (Bio-Rad Trans-blot
turbo transfer pack, Bio-Rad, Hercules, CA, USA). After blocking for 1h at room temperature in PBS,
with 0.1% (v/v) Tween 20 (PBST) and 5% milk (w/v), the membranes were incubated over night at
4 ◦C with primary antibody diluted 1:1000 in PBST with 0.5% milk or Bovine Serum Albumin (BSA).
Membranes were then washed 2 times with PBST, followed by incubation for 1–2 h at room temperature
with anti-mouse IgG (NA931V) or anti-rabbit IgG (NA934V) secondary antibody (1:10000 and 1:7000
respectively) from GE Healthcare (Chicago, IL, USA). Membranes were then washed 3 times with
PBST and all the antibodies were detected using the enhanced chemiluminescence kit ECL (GE) and
the compact darkroom ChemiDoc-It (UVP).
The primary antibodies used are listed following: CHK1 (#2345S), pCHK1 (Ser317) (#2344S), and
pCHK1 (ser345) # 2348S), CHK2(#2662S), pCHK2(#2661S), CDK1(# 28439S), CDK2 (#9112S), pCDK1
(Tyr15) (#4539S), CDC25C (#4688), CDC25A (#3652), CCNE (# 20808S), CDKN1A (#2947), γH2A.X
(Ser139) (#2577S), WEE1 (#4936S), ATM (#2873S), pATM (#5883S), ATR (#2790S), and pATR (#2853S)
from Cell Signaling. Antibody against CCNB1(ab18250) and CCNA1(ab53699) were purchased from
Abcam (Cambridge, UK). Antibody to p53 (NBP2-50538) was purchased from Novus Biologicals
(Centennial, CO, USA). Antibody to β-actin has been used as internal control and was purchased from
S igma Aldrich (St. Louis, MO, USA). For each protein the intensity of the bands was analyzed using
ImageJ software (National Institutes of Health, Bethesda, MD, USA). The relative quantity of each
protein was calculated as a ratio between the relative intensity of the protein of interest in the treated
samples divided by the relative intensity of the same protein in the controls.
2.8. Gene Expression Profiling
CHK1/CHK2 and WEE1 gene expression level was performed on total RNA isolated from BM
and peripheral blood (PBL) leukemic cells of 51 adult ALL patient samples using Affymetrix GeneChip
Human Transcriptome Array 2.0 (ThermoFisher scientific) following manufacturers’ instructions.
In detail the gene expression profile was performed on 33 BCR-ABL1-negative (23 at the time of
diagnosis and 6 unpaired relapse) and 25 BCR-ABL1-positive (16 diagnosis and 8 unpaired relapse)
samples. The normalized mRNA level was obtained using the Gene Level SST-RMA algorithm before
row data normalization with Expression Console Software 1.4 (ThermoFisher scientific).
2.9. Statistical Analysis
Statistical analyses were performed using Graphpad5 software (GraphPad Inc., San Diego, CA,
USA). For the biological experiments the data were presented as the mean ± standard deviation (SD)
obtained from the results of at least three independent biological replicates. Statistical significance
between groups was evaluated using Two-tailed t-test or One-way ANOVA test between groups.
Pearson’s correlation coefficient was used to measure the positive or negative co-expression of two
genes. In the figures statistical significance was represented as asterisks and in detail: p < 0.05 one
asterisk (*); p < 0.01 two asterisks (**); p < 0.001 three asterisks (***).
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3. Results
3.1. The Simultaneous Inhibition of CHK1, CHK2 and WEE1 Impairs ALL Cell Lines Viability and
Triggers Apoptosis
To test the efficacy of CHK/CHK2 and WEE1 inhibition we initially used ALL cell lines. Recently,
we published on the effectiveness of targeting CHK1/CHK2 kinase as a single agent in ALL models [29]
and based on that, the most sensitive (RPMI-8402) and the less sensitive (NALM-6) cell lines to the
CHK1/CHK2 inhibitor PF-00477736 were selected as models for the present study. Cells were treated
simultaneously with increasing concentrations of AZD-1775 (185 to 6 nM, 1:3 dilution series) and with
PF-00477736 (RPMI-8402: 10, 25 and 50 nM; NALM-6 250, 500 and 1000 nM) for 24, 48 and 72 h. In line
with published data [29,31–34], the simultaneous inhibition of the three target kinases resulted in
synergistic reduction of cell viability (Figure 1A). Chou-Talalay analysis showed that the combination
index (C.I.) values were between 0.17 (strong synergism) and 0.9 (slight synergism) (Table S1). We next
confirmed that the reduction of cell viability correlated with a statistically significant reduction of
cell growth (Figure 1B) and induction of apoptosis (Figure 1C) specifically in samples treated with
PF-0477736 plus AZD-1775 (hereafter PF + AZD). The effect of the combination in terms of induction
of apoptosis was greater in RPMI-8402 cells (47% apoptotic cells) compared with NALM-6 cells (27%
apoptotic cells). To understand the difference in the apoptotic response, we evaluated several intrinsic
characteristics of the two cell lines which may mediate the responsiveness to the combination treatment.
In relation to the three target kinases, the two cell lines were comparable in terms of copy number
alteration (Figure S1A), transcript level (Figure S1B) but not protein expression. Notably, the basal
protein expression of WEE1 was higher (4-fold) in RPMI-8402 in comparison to NALM-6 cell line
suggesting that the former cell line may have greater dependency on WEE1.
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RPMI-8402 and NALM-6 cell lines treated for 24 h with AZD-1775 (185 nM) and PF-00477736 (25 and 
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3.2. The Inhibition of CHK1, CHK2 and WEE1 Kinases Affect Early S-phase Regulation Cells
To understand the consequences of CHK1/CHK2 and WEE1 inhibition on cell cycle progression,
cells were analyzed for DNA content using PI staining. The PF + AZD treatment significantly decreased
the number of cells in G1 and significantly increased the number of cells in S phase, thereby confirming
the combination impaired cell cycle progression (Figure 2A,B). Immunoblotting analysis revealed that
the combination treatment stabilized the CDK2-CYCLIN E complex, master regulator of the G1/S
transition [35,36], resulted in the increase of CYCLIN E and CDK2 levels as compared to the single
agents and controls. In detail, CDK2 level was increased by the treatments reaching the higher level in
the combination treatment in both cell lines. Similar results were found for CYCLIN E protein level on
RPMI-8402 cells. In NALM-6 cell, no difference was found between combination treatment and AZD
alone in term of CYCLIN E1 level (Figures S1C and S4). In line with the cell cycle data, no significant
difference was seen in the levels of CDK1-CYCLIN B complex (master regulator of the G2/M transition)
between single and PF + AZD treatments. In both cell lines, PF + AZD treatment reduced the amount
of CYCLIN A1 in comparison to the single treatment and to the controls (Figure 2C, Figures S1C
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and S4). To further investigate the effect of the combination on cell cycle progression, cells treated
with PF, AZD, and their combination for 24 and 48 h, were incubated with BrdU to directly assess
the effects on DNA replication. For NALM-6 cells, treatment with inhibitors for 24 h did not affect
BrdU incorporation when compared to untreated controls. At 48 h, both single treatments reduced
BrdU incorporation suggesting inhibition of replication. However, the combination treatment restored
replication to control levels, suggesting overriding of the DNA damage checkpoint by the single agents.
In RPMI-8402 cells, single treatment slightly elevated BrdU incorporation relative to control at both
24 and 48 h. Unlike NALM-6 cells, treatment with the PF + AZ combination for 24 h significantly
increased BrdU incorporation in comparison to control and single agent. For samples treated with
single or the combination for 48 h, BrdU incorporation was elevated when compared to untreated
control. These results suggest that the inhibitors do not inhibit DNA replication, and is consistent
with the increase in S phase cells (Figure 2D). Finally, to further evaluate the potentials of this new
therapeutic strategy, ALL cell lines were treated with methotrexate (MTX) after being exposed to
PF-00477736 and/or AZD-1775. MTX is a selective inhibitor of folic acid and it has been showed to
reduce both purine and pyridine pools [37]. The scientific rationale for this drug regimen was to
exploit the S-phase enhancement of the combination to increase the replicative stress and to enhance
replicative forks collapse. Interestingly, the inhibition of CHK1/CHK2 or WEE1 in single agent or in
combination enhanced the cytotoxicity of MTX (Figure 2E).
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3.3. The Combination AZD-1775 and PF-00477736 Triggers the S Phase Checkpoint and Induce DNA Damage
We then analyzed the effects of the simultaneous inhibition of CHK1, CHK2 and WEE1 on the
DDR pathways and the induction of DNA damage. Single agent treatments only weakly induced
the phosphorylation of H2AX (ser139), a bona fide marker of DNA damage, in comparison with
the combination treatment (Figure 3A, Figures S2 and S5). Sub-toxic concentrations of AZD-1775
alone significantly activated CHK1 kinase (phosphorylation at ser345 or ser317)-dependent response,
which was also observed in the combination treatment. The combination treatment did not increase
phosphorylation in ser345, necessary for the nuclear localization of CHK1, in both the cell lines.
Moreover, the drug combination significantly increased ser317 phosphorylation which is one of the
crucial events after stalled replication forks and is specifically mediated by ATR kinase [38]. Taking into
account total levels o CHK1, the amount of phospho-CHK1 ser317 appear to be significantly highest
in the combination treatment. C nsistent with their ability to overrid the DNA dama e checkpoint
arrest, the inhibition of both CHK1/CHK2 and WEE1 additively reduced the ount of ph spho-CDK1
(Tyr15) in oth cell lines [39] (Figures S2 and S5). Chang s w re also observed in CHK2 activity and
stability in the PF + AZD treated with a different outcome among the two cell lines. In RPMI-8402 cells
the single treatments increased the amount of phospho-CHK2 while the co-treatment did not further
increase the levels of phospho-CHK2. However, when the total levels of CHK2 is taken into account,
the amount of phospho-CHK2 appear to be highest in the combination treatment. In NALM-6 cells, the
basal level of phospho-CHK2 in untreated cells is high. Both single and co-treatment reduced the level
of phospho-CHK2. This however, is due to the dramatic reduction in the total levels of CHK2 after
treatment with inhibitors. The heterogeneous effect of both single treatments and combination of CHK2
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was likely related to the protein expression of the up-stream activator, ATM. Indeed, in RPMI-8402 cells
the combination treatment additively increased the amount of both basal and phospho-ATM (ser1981)
while decreased them in NALM-6 cells (Figure 3A, Figures S2 and S5).
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3.4. The Effect of the Combination Is Independent the Activity of p53 in the Regulation of Cell Cycle
TP53 is mutated in 16% of adult ALL patients and it has been showed to correlate with poor
prognosis [40–42]. P53 is phosphorylated during cell cycle checkpoint activation in response to DNA
damage by ATM/ATR [43–45] and by CHK1/CHK2 [46,47]. We therefore studied the role of p53 activity
in cell cycle regulation following drug treatments. AZD + PF treatment increased the amount of
phospho-p53 (ser15) but not of phospho-p53 (ser20) in both cell lines. These findings highlighted that
p53 is activated in both cell lines in response to DNA damage by the activity of ATR and ATM (increase
of phospho-p53 ser15), but its complete activation, necessary for its transcriptional activity, was
compromised (decrease of phospho-p53 ser20) [48,49]. In RPMI-8402 cells, which are TP53-mutated
(NM_000546.5: c.817C>T; p.Arg273Cys), the combination also promoted a significant increase in the
total level of p53 relative to control and single agent treatments. The missense mutation, located in the
DNA binding domain, prevents the activation of the downstream DNA damage response pathway. This
explains the absence of activation of crucial downstream targets like p21 [50,51] and CDC25A [52–54]
in all samples. Conversely, in the TP53 proficient NALM-6 cells, the inhibitor combination reduced the
basal amount of p53. This then leads to loss of p21 expression which in turns accounts for the increased
expression of CDC25A (Figure 3B, Figures S3A and S6). It has been also shown that p53 promotes
CDC25A down-regulation in response to DNA damages, through the activation of the transcriptional
repressor ATF3 [52].
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3.5. CHK1 and WEE1 Are Co-Expressed in ALL Primary Cells
To further evaluate whether CHK1/CHK2 and WEE1 could be therapeutic targets in ALL, we first
assessed the level of expression of these kinases in primary leukemic ALL samples. We previously
showed that all three kinases are highly expressed in ALL samples in comparison to normal mononuclear
cells [28,55] but we did not investigate their level of co-expression. Here, in primary leukemic blasts
isolated from the bone marrow (BM) or the peripheral blood (PB) of adult B-ALL patients (for patient
characteristics see [28]) at diagnosis (n = 39) and relapse (n = 14; not paired samples) we observed
that Wee1 and Chek1 transcripts are co-expressed at diagnosis (Pearson r = 0.5770, p = 0.0001) and
strongly co-expressed at relapse (Pearson r= 0.8919; p = 0.0001) (Figure 4A). Based on the results of the
functional studies on ALL cell lines, we then evaluated the co-expression of different elements involved
in the regulation of the DDR pathways (Table S2). The results of the analysis showed high level of
positive co-expression between Chek1/Chek2/Wee1 and several genes involved in the DDR pathway
(Tables S3 and S4).
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Figure 4. The inhibition of CHK1, CHK2 e WEE1 compromises primary leukemic B-ALL clonogenic
capacity. (A) Dot plot showing the Pearson correlation (r value) of Wee1 and Chek1 relative mRNA level
in primary leukemic ALL samples at diagnosis (n = 39) and at relapse (n = 14). On the top of each dot
plot is reported the statistical significance of the analysis and on the linear regression is reported in red
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the Pearson correlation value (r). (B) Clonogenic assays of primary leukemic cells isolated from the
bone marrow of adult B-ALL patients (n = 7). The columns represent the normalized number of
colonies in the treated samples in relationship to the control. The asterisks in the graph represent how
the effect of the combined treatment in the reduction of the number of colonies is significantly different
from the single treatments and from the un-treated control. (C) Scatter plot representing the mean of
7 independent experiments. In the graph AZD-1775 in combination with PF-00477736 is named AZD +
PF. In the figures statistical significance was represented as asterisks and in detail: p < 0.05 one asterisk
(*); p < 0.01 two asterisks (**); p < 0.001 three asterisks (***).
3.6. Inhibition of CHK1/2 and WEE1 Affect the Clonogenic Capacity of Primary ALL Cells
Primary mononuclear cells isolated from the BM of B-ALL patients (n = 7, Table S5) at diagnosis
or relapse (not paired) were seeded in methylcellulose-based medium and treated for 14 days with
PF-00477736 (0.1 µM) with or without AZD-1775 (0.1 µM). Based on the average number of colonies
counted in the single treatments and in the combined treatment, the clonogenic assays are consistent
with the effect of the drug combination in cell viability assays. On primary leukemic cells the effect of
the combination in term of reduction of number of colonies resulted additive (Figure 4B,C). We sought
to correlate the in vitro sensitivity to the combination with the patient-relative expression of the three
targets genes, we performed quantitative PCR analyses. However, no significant association was
identified (Figure S3C). To better define the effect of the in vitro treatments on BM hematopoietic
precursors the colonies were harvested after 14 days and stained with MC Grunwald & Giemsa
solution. According to the routine diagnostic procedure [56], the slides were analyzed for the count of
hematopoietic precursors, primary leukemic blasts and hematopoietic cells based on cell morphology.
The morphological staining confirmed a reduction of leukemic cells’ count in the combinations
compared with the single agent treatments and the control (Figure S3C). Moreover, the number of
promyelocytes was not affected, while monocytes/macrophages showed a trend towards increased
amount, while the number of undefined precursors was significantly reduced by the drug (Figure S3C).
4. Discussion
The identification of novel therapeutic strategies for the treatment of ALL patients who relapse
after standard of care therapy is an urgent clinical need. Although the initial response to treatments
is generally positive, a large percentage of patient relapses or becomes refractory to conventional
therapies and the identification of novel functional and molecular targets could improve the outcome
of ALL patients. Our group, together with many others, is currently focusing on applying the concept
of synthetic lethality to selectively target cancer cells. In the scenario of two pathways regulating
a crucial biological function, the inhibition of one pathway is compensated by the second pathway.
However, the simultaneous inhibition of both pathways results in the complete loss of the biological
function. Several genes are involved in the regulation of the cell cycle checkpoints. These genes
cooperate in the regulation of common substrate. For example, CDK1 and CDK2 activity is known
to be regulated directly by the inhibitory phosphorylation promoted by WEE1 and PKMYT1, and
indirectly by CDC25 family proteins. We previously reported the efficacy of selective CHK1/CHK2 or
WEE1 inhibitors in disrupting the cell cycle checkpoint control [28,29,31]. Indeed, the inhibition of
checkpoint functionality increased the genetic instability to a point of no return. In the present study
we speculated that the simultaneous inhibition of CHK1/CHK2 and WEE1 kinases could synergistically
impair the functionality cell cycle checkpoint, inducing massive DNA damage and resulting in cell
death. Indeed, it has been showed that WEE1 inhibition results in stalled replication forks that can
eventually collapse [26]. In turn, this activates CHK1 to presumably help coordinate the repair of
these damaged sites. In this scenario, co-treatment with a WEE1 and a CHK1 inhibitor blocks the
cells ability to repair the damage, thus inducing apoptosis. This hypothesis was confirmed by the
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synergistic reduction of cell viability observed in NALM-6 and RPMI-8402 cell lines, along with
significant induction of cell death in the samples treated with the drugs combination.
4.1. The Inhibition of CHK1/WEE1 Kinases Highlights Potential Therapeutic Strategies Affecting S Phase
Cell cycle analysis showed that the two inhibitors increased the number of cells in S phase while
decreasing the number of cells in G1 while no significant effect was seen in the percentage of cells in
G2/M phase. This may be due to the low number of cells in this phase in both cell lines. To characterize
the effect of PF-0477736 with AZD-1775 on cell cycle, samples were analyzed for the expression of
CDK-Cyclin complexes. Our result showed that in both cell lines the co-treatment synergistically
increased CDK2 and/or Cyclin E1 protein expression. Therefore, we speculate that the increase
of CDK2/Cyclin E1 expression marks the action of the combination in the early S phase. Indeed,
CDK2/Cyclin E1 complex promotes the assembly of the pre-replication complex (CDC6/MCM2-7) on
the origin of replications during the transition from G1 to S phase [36,57]. Immunoblotting analysis
also highlighted the potential cytotoxic effect of the combination. Indeed, in both cell lines a synergistic
induction of γH2AX was seen in the samples treated with PF-0477736 and AZD-1775, consistent with
the notion that enhanced DNA damage occurs through induction of break sites and block of repair.
The induction of DNA damage was also indicated by the activation of ATR/CHK1 and ATM/CHK2
pathways. The result of the combination studies highlighted that simultaneous inhibition of WEE1 and
CHK1 sensitize the ALL cell lines to S-phase specific chemotherapy agents. We have already published
regarding the strong synergism using AZD-1775 or other cell cycle checkpoint kinase inhibitors in
combination with different chemotherapy agents. Here, we showed that the cytotoxicity PF-0477736
with AZD-1775 can be enhanced using MTX. We hypothesized that the accumulation of cells in S phase
may increase the intracellular demand for nucleotides tri-phosphate and thus the use of MTX should
results in strong reduction of the cell viability. We believe that similar results may be obtained using
antimetabolites such as clofarabine or nelarabine
4.2. The Efficacy of the Combination Strategy Is Independent to p53 Functionality in ALL Cell Lines
Interestingly, the effect of the combination was p53- and p21-independent. Indeed, immunoblotting
analysis showed that the co-treatment triggered the ATM/ATR pathway as showed by the induction
of phospho-p53 (ser15). The inhibition of CHK1/CHK2/WEE1 functionality was confirmed by the
reduction of phospho-p53 (ser20). Regarding the basal amount of p53, the combination increased it
synergistically in RPMI-8402 while reduced it on NALM-6 cell line. In RPMI-8402 cells, TP53 mutated,
the missense mutation in the DNA binding domain affected the p53 downstream DDR pathway
(absence of p21 or CDC25A) resulting in no differences between samples treated with the two inhibitors
either in single agent or in combination. Conversely, in NALM-6 cells, p53 proficient, the combination
reduced the basal amount of p53, and consequently, the amount of p21 (resulting in a significant
increment of CDC25A). In normal conditions p21 would bind to CDK2-Cyclin E1 complex to induce
cell cycle arrest (G1/S) [58] (Figure 5).
4.3. Limiting the Toxicity of CHK1/WEE1 Inhibition Using Combination Strategies
Currently the use of cell cycle checkpoint or other DDR inhibitors is raising questions about
their potential toxicity. Indeed, the inhibition of DDR pathway may expose healthy cells to the risk
of accumulation of DNA damages. In our experience, the use of PF-00477736 or AZD-1775 in single
agent have limited toxicity on healthy mononuclear cells using ex vivo therapeutic concentrations.
Our combination strategies allowed to use sub-toxic concentrations of the two inhibitors to obtain
the same in vitro therapeutic effects using one of the two inhibitors in monotherapy. The effect of
the co-treatment on ALL primary leukemic cells confirmed the efficacy of the proposed therapeutic
approach. Indeed, a significant reduction of primary cell colonies was detected in samples treated with
AZD-PF. Despite the overall good response to the drug combination, its efficacy did not correlate with
the expression of the three kinases (Figure S3B). However, in patient ALL#5, the poor responsiveness to
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the combination may correlate with low number of leukemic blasts of the sample (Table S5). Although
more accurate analyses should be performed to better define the characteristics of the hematopoietic
precursors harvested from the primary colonies, the morphological analysis performed here suggested
that the reduction in the number of colonies reflected an effective decrease in the number of ALL
primary cells, with a relative low toxicity on healthy hematopoietic precursors. Finally, the gene
expression analysis of DDR-related genes highlights novel potential therapeutic option that should be
tested in ALL. In our cohort, Chek1, Chek2 and Wee1 genes are positively co-expressed with other crucial
cell cycle regulators and, in particular, with different CDKs (CDK1, CDK2 and CDK4). Numerous CDK
inhibitors have proven their efficacy in different preclinical and clinical studies against acute leukemias.
In this scenario, novel synthetic lethality approaches could be obtained by combining CDK inhibitors
with CHK1/CHK2 or WEE1 inhibitor.
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5. Conclusions
In conclusion, the idea of using targeted drug combinations to concurrently induce DNA damage
and compromise DNA repair mechanisms is currently being evaluated in clinical trials in solid
tumors (NCT03330847). In this trial cancer patients will be evaluated for the response to AZD-1775
in combination with the PARP-1 inhibitor, olaparib. Patient will be evaluated for their mutational
profile in BRCA genes or more generally in DDR-genes. Indeed, it has been showed that the synthetic
lethality approach using PARP-1 inhibition is maximum in BRCA1/2 deficient cancer patients. In this
scenario, the inhibition of PARP-1 results in the accumulation of DNA damages to a point of no
return. The addition of a WEE1 inhibitor to olaparib may force cancer cells to proliferate in the
presence of PARP1-mediated DNA damages resulting in a massive induction of cell death. Our data
suggest that the combination of CHK1/CHK2 and WEE1 inhibitors may cause a similar functional
impairment, thus providing the rationale for its evaluation in clinical trials for adult ALL patients. Our
therapeutic approach exploits the intrinsic genetic instability of ALL cells, forcing them to replicate
and to progressively accumulate DNA damages during DNA synthesis.
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Abbreviations
ALL acute lymphoblastic leukemia
BM bone marrow
B-ALL B-cell precursor acute lymphoblastic leukemia
DDR DNA damage response
PB peripheral blood
PI Propidium Iodide
SD standard deviation
SER serine
T-ALL T-cell precursor acute lymphoblastic leukemia
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